SCYXSCYNEXIS, Inc.

$38M

Q2 2023 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$131M+9836.1% YoY

Gross Profit

$131M99.7% margin

Operating Income

$117M88.6% margin

Net Income

$122M93.0% margin

EPS (Diluted)

$2.46

QoQ Revenue Growth

+11533.1%

Cash Flow

Operating Cash Flow

$74M

Free Cash Flow

$74M

Stock-Based Comp.

$728,000

Balance Sheet

Total Assets

$155M

Total Liabilities

$62M

Stockholders' Equity

$93M

Cash & Equivalents

$58M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$131M	$1M	+9836.1%
Gross Profit	$131M	$1M	+11013.5%
Operating Income	$117M	-$22M	+636.0%
Net Income	$122M	-$13M	+1016.1%

Revenue Segments

License and Service

$131M100%

Product

$468,0000%

SCYX Q2 2023 Earnings — SCYNEXIS, Inc. Revenue & Financial Results | Market Cap Arena